Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase III study supports once-daily dosing of darunavir/ritonavir in HIV-1 infection

March 2, 2010

Efficacy and safety results of ecallantide treatment for hereditary angioedema attacks

March 2, 2010

Enhanced-sensitivity Trofile assay and HIV V3-loop sequencing comparably predict maraviroc response

March 2, 2010

Fluticasone nasal spray ineffective in irritant rhinitis in pilot trial

March 1, 2010

C5A inhibits HIV-1 and HSV in preclinical studies

March 1, 2010

Vicriviroc does not meet primary endpoint in two phase III trials in HIV

March 1, 2010

QNL-111 shown to inhibit HIV-1 DNA integration

March 1, 2010

Truvada well tolerated in HIV-1-infected pregnant women and neonates

March 1, 2010

Ofatumumab shows clinical effects with and without fludarabine in CLL

Feb. 26, 2010

Prime/boost HIV vaccine shows high immunogenicity in healthy volunteers in phase I/II trial

Feb. 26, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...